
2022–2023 PCRS ANNUAL REPORT





OUTGOING PRESIDENT'S MESSAGE

Greetings -

I trust this message finds you all in good health and high spirits.

It has been a genuine honor to serve as the President of our esteemed Society. My parting message is one of gratitude.

I wish to express my heartfelt thanks to the incredible team at SBI Management, whose unwavering dedication and support have played a pivotal role in the success of our society. Your hard work behind the scenes does not go unnoticed, and I am deeply grateful for your tireless efforts.

I would also like to extend my thanks to the dedicated members of the PCRS Board of Directors, who have been instrumental in guiding our society toward excellence.

A special mention is owed to the 2022 Program Committee, whose innovative ideas and tireless efforts ensured our annual meeting was a resounding success. It was a privilege to work alongside such a talented and dedicated group of individuals.

Lastly, I want to express my appreciation for our invaluable industry partners, whose support has been crucial in advancing our mission and fostering collaboration within our community. Your contributions have made a meaningful difference in the lives of countless patients.

I am excited to share that a significant personal change awaits me on the horizon. I will be relocating to the southeast, where I will embark on a new path in my professional journey. However, please know my commitment to the PCRS remains steadfast. The PCRS annual meeting has always been the highlight of my professional year and I fully intend to continue attending.

I leave the society in the capable hands of our new leaders, President Tamara Tobias and President-Elect Alex Quaas. I have every confidence they will continue to steer our society toward greater heights and ensure our mission to advance reproductive medicine endures.

Wishing you all continued success, good health, and prosperity.

Warm regards, Paul S. Dudley, M.D. Past President, PCRS



CURRENT PRESIDENT'S MESSAGE

Dear PCRS Members & Supporters,

It is with great pleasure to update you on several happenings with PCRS. The Society is flourishing and this past March we held a Strategic Planning Meeting with 22 PCRS members participating, including the PCRS Board of Directors, SBI Association Management, and Dr. Steve Swafford from Leadership Outfitters. Key initiatives included promoting a culture of inclusivity and collegiality, nurturing, and developing creativity and innovation, creating value with sustainable growth, and providing guidance, mentorship, and leadership to the society. Specific action items will be achieved with collaboration from the PCRS Board of Directors and assigned committees which include the Program, Abstract, Grant, Scholarship and Awards, Social Media Communications, and Membership Committees.

The theme for next year's PCRS Annual Meeting is Innovation and Integration ~ the Future of Reproductive Medicine. Reproductive medicine is exploding with innovation and advancements in genetics, artificial intelligence, and continuous research. Integration of all multidisciplinary teams is essential. Led by Debbie Venier, the PCRS Planning Committee is preparing an excellent program for 2024 featuring lectures, abstracts, debates, and networking opportunities. March 2024 will be the 40th Anniversary of the first birth from a frozen embryo, Zoe Leyland, born March 28, 1984, in Australia. Anticipate some frozen themes.

The 2023 PCRS Annual Meeting was a remarkable success including 77 sponsors and exhibitors who showcased their latest innovations and contributions to our field and provided us with opportunities to learn and network. A special thank you to the following sponsors: Ferring Pharmaceuticals (Diamond), EMD Serono (Ruby), Organon, Reproductive Health Center, and Coopersurgical (Topaz) and Walgreens/Alliance Rx, ExEm Foam, Ovation Fertility, TMRW Life Sciences, The Permanente Medical Group, BabySentry, and IVF Store (Supporting).

Thanks to Ferring Pharmaceuticals for their generous research grant, PCRS was able to award 2 recipients grants to support their innovative projects in reproductive medicine and we have received 13 submissions for 2024 currently under review by our Research Grant Committee.

Lastly, I would like to thank the PCRS Board of Directors and SBI Association Management for all their contributions.

Respectfully submitted, Tamara Tobias, ARNP President, Pacific Coast Reproductive Society



ORGANIZATIONAL MISSION, VISION, GLOBAL GOALS, VALUES, PURPOSE



SUPPORTIVE

- Member and Sponsor supported scholarship program for REI Fellows and other trainees to attend Annual Meeting
- Leadership development through Junior and Senior level committee service and Board Directorship
- Concierge service for attendees, exhibitors, and sponsors

INNOVATIVE

- Website enables convenient, time-effective online interactions with members, attendees, faculty, authors, volunteers exhibitors and sponsors
- Program Planning committee members rotate each year to provide fresh and timely educational activities and content

INCLUSIVE

- Complimentary membership to all REI trainees; discounted membership to allied healthcare teammates
- PCRS Board and Committees reflect an inter-professional workforce, including physicians, biologists, nurses, counselors, and practice management
- Members include medical students, residents, fellows, both practicing and retired physician, and allied health professional

COLLEGIATE

- PCRS Demands an even playing field among REI professionals
- Relationships with SGI, ASRM, CFS, and Fertility & Sterility provide gateways of advancement and partnership for PCRS members
- PCRS Annual Meeting Evaluations contribute to efficacy of REI field of medicine

PROFESSIONAL

- PCRS CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME to physicians
- Nurse and genetic counselors may apply for CEUs from their appropriate accrediting bodies with their PCRS certificate of attendance
- Abstracts published by PCRS are peer-reviewed and selected by an interprofessional committee of REI experts


INTIMATE

- PCRS sessions teach to the team of individuals in reproductive medicine
- Informal dress code promotes an environment of collegiality and solidarity
- Annual Meeting blends education with networking to allow ample learning and opportunity to build and foster relationships

ABSTRACT SUBMISSION

PCRS continues to be a global, interactive organization promoting leadership and innovation in reproductive medicine within a collegial environment. The annual CME program is based on the integration of clinical practice, scientific research, and education in the field of reproductive medicine.

More than one hundred and twenty abstracts were selected for oral or poster presentation at the 2023 annual meeting and were also published in a special digital edition of *Fertility & Sterility*.



Abstract Submissions

SCHOLARSHIP PROGRAM

To encourage the participation of medical professionals in-training, particularly fellows specializing in reproductive medicine, PCRS established a Scholarship Program made possible by funding from Society members and commercial sponsors.

Scholarship Types & Eligibility Requirements

MD Scholarship

Open to all fellows in US REI programs, residents, and medical students who have not previously attended PCRS on a scholarship.

Merit Scholarship

Open to any PCRS scholarship winners from previous years who will be the presenting author of an abstract submitted for presentation at the meeting.

REI Lab Scholarship


Open to all non-management IVF laboratory professionals who are the presenting author of an abstract submitted for presentation at the meeting.

Nurses and Genetic Counselors


Open to all nurses and genetic counselors who have not attended a PCRS meeting in the past or are the presenting author of an abstract submitted for presentation at the meeting.

SCHOLARSHIPS AWARDED

Scholarships Awarded



SCHOLARSHIP PROGRAM




Scholarship Program

SPONSORED RESEARCH GRANTS


PCRS supports innovative research projects in reproductive medicine for current Reproductive Endocrinology, Infertility Fellows and New Investigators who have completed their professional training in the last three years. The generous donation from Ferring Pharmaceuticals Inc, enables PCRS to award \$20,000 in annual research grants. Funds are available for project expenses, technical assistance, patient express, research supplies, and durable laboratory equipment.

PCRS Research Grants are sponsored by Ferring Pharmaceuticals, Inc.

Sponsored Research Grants




COMMERCIAL SPONSORS




Commercial Sponsors

REVENUE FROM EXHIBIT FEES





REVENUE FROM ATTENDEE FEES



ENDOWMENT FUND BALANCE

Endowment Fund






DUES REVENUE

OTHER REVENUES

Other Revenue Streams



KEY FINANCIAL STATISTICS

	2016- 2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023
RESERVES	1,034,536. 03	1,004,614.00	859,522.29	901,381.78	1,310,148.82	957527.47	1047000.5
OPERATING EXPENSES	204,576.0 0	295,401.00	285,593.89	320,837.90	198,143.53	260151.67	246618.43
RATIO	5.06	3.40	3.01	2.81	6.61	3.68	4.25
INCOME	1,021,242. 18	956,782.00	963,087.51	42,462.04	213,846.53	914316.82	878151.15
EXPENSE	866,184.0 0	1,006,107.00	693,573.62	1,850,454.00	258,081.13	727543.53	792591.54
COMMERCI AL SUPPORT	432,350.0 0	345,690.00	300,550.00	0.00	103,595.00	232700	207650
PROGRAM REVENUE	511,237.0 0	535,312.00	206,655.00	2,015.00	36,945.00	238764	256050
DUES	47,155.00	41,855.00	54,000.00	28,325.00	14,800.00	57135	55490
MEMBER MEETING ATTENDAN CE	271	271	312	0	238	145	215
ACTIVE MEMBERS	224	187	215	318	235	364	334
MEMBER RETENTION %							
,0	69.7%	78.1%	71.2%	92.8%	78.3%	92%	91%

BALANCE SHEET

		Jun 30, 23	Jun 30, 22	\$ Change	% Change
	ETS				
Сι	current Assets				
	Checking/Savings				
	1010 · Business Premium Market Rate	86,986.02	86,934.87	51.15	
	1030 · Wells PCRS Checking 5963	343,941.48	325,939.96	18,001.52	5.52%
	Total Checking/Savings	430,927.50	412,874.83	18,052.67	4.37%
	Other Current Assets	17 000 50	1 0 0 0 0 0	10.000 50	0.40 500
	1300 · Prepaid Fees	17,622.50	4,000.00	13,622.50	
	Total Other Current Assets	17,622.50	4,000.00	13,622.50	
_	otal Current Assets	448,550.00	416,874.83	31,675.17	7.6%
Fi	ixed Assets				
_	1500 · Asset /Web-Site Development	30,000.00	30,000.00	0.00	0.0%
	1550 · Equip & Fixed Asset Accum. Depr	-30,000.00	-30,000.00	0.00	
Тс	otal Fixed Assets	0.00	0.00	0.00	0.0%
Ot	other Assets				
	1600 · Investments				
	Holdings - Scholarship Endowmen				
	Schola End Unrealized Gain/Loss	49,754.76	38,506.52	11,248.24	29.219
	Scholar Endow - Vanguard	124,843.00	124,843.00	0.00	0.0%
	Scholar Endowment Dividends	14,242.41	9,353.00	4,889.41	52.289
	Total Holdings - Scholarship Endowme	n 188,840.17	172,702.52	16,137.65	9.349
	1610 · Holdings - Investment Fund				
	1615 · Inv Fund Unrealized Gain/Los	s 200,286.54	149,170.42	51,116.12	34.279
	1620 · Investment Fund Dividends	57,873.79	35,654.53	22,219.26	62.329
	1630 · Investments Fund	600,000.00	600,000.00	0.00	0.09
	Total 1610 · Holdings - Investment Fund	d 858,160.33	784,824.95	73,335.38	9.34%
	Total 1600 · Investments	1,047,000.50	957,527.47	89,473.03	9.34%
Тс	otal Other Assets	1,047,000.50	957,527.47	89,473.03	9.349
OT/	ALASSETS	1,495,550.50	1,374,402.30	121,148.20	8.82%
IAB					
	iabilities				
Lia	labilities				
Li	Current Liabilities				
LI					
Lli	Current Liabilities	16,248.23	1,067.67	15,180.56	1,421.849
	Current Liabilities Accounts Payable	16,248.23 16,248.23	1,067.67		
	Current Liabilities Accounts Payable 2000 · Accounts Payable		,		-
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable		,		
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities		1,067.67		1,421.849
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues	16,248.23	1,067.67	15,180.56	1,421.849
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022	16,248.23	1,067.67 15,815.00 15,815.00	15,180.56	1,421.849 -100.09 -100.09
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues	16,248.23 0.00 0.00	1,067.67 15,815.00 15,815.00 53,250.00	15,180.56 -15,815.00 -15,815.00	1,421.849 -100.09 -100.09 -100.09
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting	16,248.23 0.00 0.00 0.00	1,067.67 15,815.00 15,815.00 53,250.00	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00	1,421.849 -100.09 -100.09 -100.09 -100.09
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities	16,248.23 0.00 0.00 0.00 0.00 16,248.23	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities Total Current Liabilities	16,248.23 0.00 0.00 0.00 0.00	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities Total Uther Current Liabilities Total Uther Current Liabilities Total Uther Current Liabilities	16,248.23 0.00 0.00 0.00 0.00 16,248.23 16,248.23	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67 70,132.67	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44 -53,884.44	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839 -76.839
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities otal Liabilities quity 3001 · Fund Balance - Unallocated	16,248.23 0.00 0.00 0.00 0.00 16,248.23 16,248.23 16,248.23 91,425.94	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67 70,132.67 258,238.18	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44 -53,884.44	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839 -76.839 -76.839 -76.839
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities otal Liabilities quity 3001 · Fund Balance - Unallocated 3050 · Investment Fund	16,248.23 0.00 0.00 0.00 0.00 16,248.23 16,248.23 16,248.23 91,425.94 830,164.15	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67 70,132.67 258,238.18 883,651.89	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44 -53,884.44 #################################	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839 -76.839 -76.839 -64.69 -64.69
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities Other Current Liabilities	16,248.23 0.00 0.00 0.00 0.00 16,248.23 16,248.23 16,248.23 91,425.94 830,164.15 200,000.00	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67 70,132.67 258,238.18 883,651.89 200,000.00	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44 -53,884.44 -53,884.44 -53,884.74 0.00	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839 -76.839 -76.839 -64.69 -60.59 0.09
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities otal Liabilities quity 3001 · Fund Balance - Unallocated 3050 · Investment Fund 3060 · Operating Fund 3070 · Schl. Endowment Fund	16,248.23 0.00 0.00 0.00 0.00 16,248.23 16,248.23 16,248.23 91,425.94 830,164.15 200,000.00 182,679.54	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67 70,132.67 258,238.18 883,651.89 200,000.00 194,449.63	15,180.56 -15,815.00 -15,815.00 -53,250.00 -69,065.00 -53,884.44 -53,884.44 -53,884.44 -53,487.74 0.00 -11,770.09	-100.09 -100.09 -76.839 -76.839 -64.69 -64.69 -6.059 0.09 -6.059
	Current Liabilities Accounts Payable 2000 · Accounts Payable Total Accounts Payable Other Current Liabilities 2500 · Deferred Dues 2580 · Dues 2022 Total 2500 · Deferred Dues 2600 · Deferred Annual Meeting Total Other Current Liabilities Total Current Liabilities Other Current Liabilities	16,248.23 0.00 0.00 0.00 0.00 16,248.23 16,248.23 16,248.23 91,425.94 830,164.15 200,000.00	1,067.67 15,815.00 15,815.00 53,250.00 69,065.00 70,132.67 70,132.67 258,238.18 883,651.89 200,000.00	15,180.56 -15,815.00 -53,250.00 -69,065.00 -53,884.44 -53,884.44 -53,884.44 -53,487.74 0.00 -11,770.09 407,102.71	1,421.849 -100.09 -100.09 -100.09 -100.09 -76.839 -76.839 -76.839 -64.69 -6.059 0.09 -6.059 175.429

INCOME

		Annual Meeting	General	Membership	TOTAL
Ordin	nary Income/Expense				
	Income				
	4000 · Advertising	0.00	150.00	0.00	150.0
	4050 · Dues	0.00	0.00	6,220.00	6,220.0
	4100 · Interest	0.00	7.15	0.00	7.1
	Total Income	0.00	157.15	6,220.00	6,377.1
G	ross Profit	0.00	157.15	6,220.00	6,377.1
	Expense				
	5050 · Bank/Credit Card Processing Fee	0.00	375.21	0.00	375.2
	5075 · CME	14,600.00	0.00	0.00	14,600.0
	5225 · Gifts and Awards	838.20	0.00	0.00	838.2
	5325 · Management Services	0.00	17,682.00	0.00	17,682.0
	5400 · Postage and Mailing	0.00	47.56	0.00	47.5
	5425 · Printing/Duplicating	84.59	7.50	0.00	92.0
	5450 · Scholarship Expense	-175.00	0.00	0.00	-175.0
	5500 · Speaker Expenses	810.03	0.00	0.00	810.0
	5525 · Storage	0.00	93.00	0.00	93.0
	5575 · Telecommunications	0.00	110.00	0.00	110.0
	Total Expense	16,157.82	18,315.27	0.00	34,473.0
Net Ordinary Income		-16,157.82	-18,158.12	6,220.00	-28,095.9
Othe	r Income/Expense				
O	ther Income				
	7000 · Unrealized Gain/(Loss)	0.00	34,156.81	0.00	34,156.8
Т	otal Other Income	0.00	34,156.81	0.00	34,156.8
Net C	Other Income	0.00	34,156.81	0.00	34,156.8
et Inco	ome	-16,157.82	15,998.69	6,220.00	6,060.8

